The DURATION Trials: Exenatide's Foundational Diabetes Evidence
TRIAL-000018
Part of the DietApp.com GLP-1 Trial Database, a comprehensive, regularly reviewed resource.
What It Is
DURATION is the clinical trial program that established extended-release exenatide, marketed as Bydureon BCise, as an effective once-weekly alternative to the original twice-daily Byetta formulation. Both brands were discontinued in October 2024, covered in detail on their respective medication pages, but this program remains the historical evidence base for how exenatide's extended-release version was developed and validated.
Key Results
DURATION-1 compared once-weekly extended-release exenatide against twice-daily immediate-release exenatide over 30 weeks, finding greater A1C reduction with the weekly formulation, 1.9 percentage points versus 1.5, with similar weight loss of about 3.6 kg for both. DURATION-2 and DURATION-5 compared extended-release exenatide against other diabetes medications, sitagliptin and pioglitazone, again finding meaningfully greater A1C reduction with exenatide.
Why the Weekly Formulation Mattered
The DURATION program's core finding, that once-weekly dosing improved both effectiveness and, presumably, convenience compared to twice-daily injections, was the direct evidence that led to Bydureon's approval and represents an early example of the broader shift toward once-weekly GLP-1 dosing that's now standard across the medication class.
Current Status
Despite this evidence base, both exenatide brands were discontinued by AstraZeneca in October 2024. The DURATION program remains useful historical context for understanding how the field arrived at once-weekly dosing as the norm.
References
- PMC: DURATION-2, Switching From Sitagliptin or Pioglitazone to Once-Weekly Exenatide
- FDA: Bydureon Prescribing Information, Clinical Studies Section (DURATION-1 and DURATION-5 data)
Related Resources
Related Articles
Real Trial-by-Trial Results
| DURATION Trial | Comparator | Real Result |
|---|---|---|
| DURATION-1 | Twice-daily exenatide | 1.9 vs. 1.5 point A1C reduction, similar weight loss |
| DURATION-2 | Sitagliptin | Greater A1C reduction with exenatide |
| DURATION-5 | Pioglitazone | Greater A1C reduction with exenatide |
For exenatide's real cardiovascular outcomes data, see DietApp's EXSCEL trial page. For a full mechanism breakdown, see DietApp's how exenatide works explainer.
Frequently Asked Questions
Why were both exenatide brands discontinued if the evidence was strong? Discontinuation decisions often reflect market and business factors, newer, more effective GLP-1 medications, rather than the original evidence being invalidated.
Is once-weekly dosing always better than twice-daily? DURATION-1 showed real, measurably better A1C control with weekly dosing, alongside the real convenience advantage.
Does this trial data matter if the drugs are discontinued? Yes, it remains real, useful historical evidence for how the entire GLP-1 field arrived at once-weekly dosing as the current standard.
Explore More
Explore the full GLP-1 Tracker knowledge base on DietApp.com
Get Started
Explore the GLP-1 Tracker knowledge base to see the evidence behind your treatment.
About DietApp.com
DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. The information on DietApp.com is intended for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.
Last medically reviewed and updated: July 11, 2026.
duration-trials-exenatide